First Tracks Biotherapeutics, Inc. (TRAX)
| Market Cap | 696.71M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -166.09M |
| Shares Out | 34.75M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 569,243 |
| Open | 17.44 |
| Previous Close | 18.10 |
| Day's Range | 17.44 - 21.66 |
| 52-Week Range | 14.79 - 26.80 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 38.40 (+91.52%) |
| Earnings Date | Jun 1, 2026 |
About TRAX
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for TRAX stock is "Strong Buy." The 12-month stock price target is $38.4, which is an increase of 91.52% from the latest price.
News
First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
First Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runway Trading of TRAX begins on Nasdaq today SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeuti...